Sign In
Buy BVXV
$1.36
+0 (+0%)
At Close: Dec 05, 2023
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
12:00am, Thursday, 30'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs April 29)
• Arvinas Inc (NASDAQ...
Head-To-Head Contrast: BIONDVAX PHARMA/S (NASDAQ:BVXV) vs. Denali Therapeutics (NASDAQ:DNLI)
05:30am, Monday, 20'th Apr 2020
BIONDVAX PHARMA/S (NASDAQ:BVXV) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their a
New York, April 13, 2020 -- Reportlinker.com announces the release of the report "Influenza Vaccine Market Research Report by Age Group , by Vaccine Type , by Administration.
The "Worldwide Influenza Vaccines Market Size, Share, Analysis, Growth, Trends, and Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
Worldwide Influenza Vaccines Markets, 2013-2019 & 2020-2027
09:13am, Thursday, 26'th Mar 2020
Dublin, March 26, 2020 -- The "Worldwide Influenza Vaccines Market Size, Share, Analysis, Growth, Trends, and Forecast to 2027" report has been added to.
New Directors Elected to BiondVax's Board of Directors
08:01pm, Tuesday, 24'th Mar 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal influenza vaccine candidate M-001, announced that all proposed resolutions were approved at the Company's Annual General Meetin
BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial
11:15am, Thursday, 19'th Mar 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today issued an update regarding the impact of the COVID-19 pandemic on the ongoing pivotal, clinical efficacy, Phase 3 trial in Europe of the Company's M-
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that preliminary data from the Phase 2 clinical trial of BiondVax's M-001 universal influenza vaccine candidate have been published. The tr
BiondVax Announces Warrant Agreement Amendment to Permit Holders of Warrants to Exercise Both on a Cash and Cashless Basis
08:05pm, Thursday, 16'th Jan 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, announced that effe
The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
01:22pm, Wednesday, 15'th Jan 2020
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 14.) Adaptimmune Therapeutics PLC – ADR (
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter Int
BVXV: Cohort 2 of Pivotal Phase 3 Universal Influenza Vaccine Trial Fully Enrolled…
01:25pm, Wednesday, 04'th Dec 2019
By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Second Cohort of Phase 3 Trial Fully Enrolled On November 18, 2019, BiondVax Pharmaceuticals, Ltd. (NASDAQ:BVXV) anno
BiondVax Announces Third Quarter 2019 Financial Results and Business Update
12:00pm, Tuesday, 26'th Nov 2019
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its
JERUSALEM, Nov. 18, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV) announced today that enrollment and randomization of 12,463 participants in the pivotal, clinical efficacy, Phase 3 trial
Do Directors Own BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Shares?
01:14pm, Monday, 11'th Nov 2019
If you want to know who really controls BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), then you'll have to look at the...
